A federal jury ordered Takeda Pharmaceuticals U.S.A. Inc. and Eli Lilly to pay a combined amount of $9 billion in punitive damages for a failure to disclose information about the risk of bladder cancer linked to the diabetes drug Actos. In addition to punitive damages, … Full Story
Actos® is a prescription medication that is used to help control blood sugar levels in patients with type 2 diabetes. The U.S. Food and Drug Administration (FDA) has issued Actos® warnings due to the dangers of serious side effects. Actos® side effects include an increased risk of bladder cancer and heart failure in some patients.
If you or a family member has been diagnosed with bladder cancer or heart failure after long term use of this medication, you may be eligible to file a lawsuit against the manufacturer. Contact us for more information.
Actos® Drug Information
Takeda Pharmaceuticals is the manufacturer of Actos®. It has been on the market since 1999 and is used for the treatment of type 2 diabetes. It is not intended for the treatment of type 1 diabetes. Actos® works by helping the body make better use of the insulin it produces and stops the liver from producing too much sugar.
Actos® Heart Failure Information
Actos® has been linked to an increased risk of new or worsened heart failure in some patients. When evidence linked the medication to heart failure, the FDA required the manufacturer to include a black box warning about the risk. A black box is the strongest warning that the FDA mandates.
Actos® Bladder Cancer Information
Data has shown a potential risk of bladder cancer in patients who use the medication for long periods of time. The manufacturer is still conducting a study to determine the link between Actos® and bladder cancer. Initial studies which pointed to bladder cancer risks involved rats which developed tumors when given a high Actos® dosage.
Follow up studies have also shown that the risk increases as the level of Actos® dosage and the duration of treatment with the drug increases. The most comprehensive data will be developed during a 10-year study which is currently being conducted by the manufacturer. A 5-year review of the study in 2010 showed evidence of increased risk of bladder cancer in patients that used the medication for more than one year. This has led the FDA to add a warning to the packaging.
A few days before the FDA issued the warning, both France and Germany banned the sale of Actos®, based on a French study that showed the risk of bladder cancer.
Contact an Actos® Attorney
For more information about the risks associated with Actos®, contact an Actos® attorney today.
The number of lawsuit against the makers of the well-known diabetes drug Actos continues to grow as more patients come forward alleging injuries such as bladder cancer. The number of claims is still rising against Takeda Pharmaceuticals, alleging that the drug Actos used to treat … Full Story
A lawsuit has been filed against Takeda Pharmaceuticals, the manufacturers of type 2 diabetes drug Actos, on behalf of three people who died after taking the drug. Actos is the brand name for Takeda’s version of pioglitazone, which is used by diabetic patients to control … Full Story
According to a news study, published in The Archives of Internal Medicine, Avandia® and Actos® may increase the risk of vision problems in diabetes patients. Possible vision problems include macular edema, a swelling in the central part of the retina that can lead to blindness … Full Story